Overview

Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Methotrexate (MTX) is considered the 'gold-standard' drug for the treatment of severe psoriasis. Health-related quality of life (HRQOL) is impaired in patients with psoriasis, more so if disease is severe.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Narayana Medical College & Hospital
Treatments:
Methotrexate
Criteria
Inclusion Criteria:

Age range 18 to 65 years Both sexes Severe plaque-type psoriasis (BSA >10% or PASI >12) -

Exclusion Criteria:

Pregnancy Lactation Malignancy or immunosuppression including HIV Liver disease Renal
disease Non compliant Psychiatric illness Hypersensitivity to methotrexate in the past

-